The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.
 
Kenneth F. Grossmann
Consulting or Advisory Role - Array BioPharma; Bristo-Meyers Squibb; Natera; Novartis
 
Megan Othus
Consulting or Advisory Role - Cascadia Labs; Celgene; Daiichi Sankyo; Glycomimetics; Merck
Other Relationship - Celgene; Glycomimetics
 
Sapna Pradyuman Patel
Honoraria - Merck
Consulting or Advisory Role - Cardinal Health; TriSalus Life Sciences
Research Funding - Bristol-Myers Squibb (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); InxMed (Inst); Novartis (Inst); Provectus (Inst); Reata Pharmaceuticals (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - Cardinal Health; Clinica Santa Maria; Merck
Other Relationship - Immunocore
 
Ahmad A. Tarhini
Consulting or Advisory Role - Array BioPharma; BioNTech; Bristol-Myers Squibb; Genentech/Roche; Immunocore; Merck; Novartis; Partner Therapeutics; Pfizer/EMD Serono; Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); OncoSec (Inst); Prometheus (Inst); Sanofi/Regeneron (Inst)
 
Vernon K. Sondak
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Merck/Schering Plough; Novartis; Regeneron; Replimune
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Polynoma; Replimune
 
Teresa M. Petrella
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Pfizer; Sanofi/Regeneron; Sun Pharma
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Pfizer; Sanofi/Regeneron; Sun Pharma
Research Funding - Novartis Canada Pharmaceuticals Inc; Roche Canada
 
Thach-Giao Truong
No Relationships to Disclose
 
Nikhil I. Khushalani
Stock and Other Ownership Interests - Amarin Corporation; Asensus Surgical; Bellicum Pharmaceuticals; Mazor Robotics
Honoraria - Sanofi
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Immunocore; Incyte; Iovance Biotherapeutics; Jounce Therapeutics; Merck; NCCN/Pfizer; Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst)
 
Justine Vanessa Cohen
Consulting or Advisory Role - Bristol-Myers Squibb; Genzyme
 
Elizabeth Iannotti Buchbinder
Employment - Alexion Pharmaceuticals (I)
Consulting or Advisory Role - Apexigen; Bristol-Myers Squibb; Novartis; Shionogi
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Genentech/Roche; Lilly; Novartis
 
Kari Lynn Kendra
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Pauline Funchain
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst)
 
Karl D. Lewis
Honoraria - Array BioPharma; Iovance Biotherapeutics
Consulting or Advisory Role - Array BioPharma; Iovance Biotherapeutics; Merck; Regeneron; Roche; Sanofi
Research Funding - alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Kartos Therapeutics (Inst); Merck (Inst); Nektar (Inst); Neon Therapeutics (Inst); OncoSec (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech (Inst); Senhwa Biosciences (Inst); Ultimovacs (Inst)
Travel, Accommodations, Expenses - alkermes; Merck; Neon Therapeutics; Regeneron; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Regeneron; Roche/Genentech
 
Bartosz Chmielowski
Consulting or Advisory Role - Deciphera; Epizyme; Genentech; IDEAYA Biosciences; Iovance Biotherapeutics; Nektar; OncoSec; Sanofi
Speakers' Bureau - Sanofi/Regeneron
Research Funding - Advenchen Laboratories (Inst); Aeglea Biotherapeutics (Inst); Array BioPharma (Inst); Ascentage Pharma (Inst); Atreca (Inst); Biothera (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); IDEAYA Biosciences (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Neon Therapeutics (Inst); Novartis (Inst); PACT Pharma (Inst); RAPT Therapeutics (Inst); Replimune (Inst); Rgenix (Inst); Tolero Pharmaceuticals (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Deciphera; Epizyme; Regeneron
 
Hongli Li
No Relationships to Disclose
 
James Moon
No Relationships to Disclose
 
Krishna Soujanya Gunturu
Consulting or Advisory Role - Cancer Support Community; Eisai; Lilly
Travel, Accommodations, Expenses - Eisai; Lilly
 
Zeynep Eroglu
Consulting or Advisory Role - Elsevier; Genentech/Roche; Natera; Novartis; OncoSec; Regeneron; Sun Pharma
Research Funding - Novartis (Inst); Pfizer (Inst)
 
John M. Kirkwood
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Elsevier; Harbour BioMed; Iovance Biotherapeutics; Istari Oncology; Novartis; OncoSec; Pfizer; Scopus BioPharma
Speakers' Bureau - BMS
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Checkmate Pharmaceuticals (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Antoni Ribas
Leadership - Arcus Biosciences; Lutris; PACT Pharma
Stock and Other Ownership Interests - 4c Biomed; Advaxis; Arcus Biosciences; Compugen; CytomX Therapeutics; Five Prime Therapeutics; Highlight Therapeutics; ImaginAb; Isoplexis; Kite/Gilead; Lutris; MapKure; Merus; PACT Pharma; RAPT Therapeutics; Rgenix; Tango Therapeutics
Honoraria - Amgen; AstraZeneca; Chugai/Roche; Genentech/Roche; Merck Sharp & Dohme; Novartis; Sanofi; Vedanta Biosciences
Consulting or Advisory Role - Amgen; Chugai Pharma; Merck; Novartis; Sanofi
Research Funding - Agilent (Inst); Bristol-Myers Squibb (Inst)